Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 121,300 shares, a growth of 46.5% from the October 15th total of 82,800 shares. Currently, 4.8% of the company’s stock are sold short. Based on an average daily trading volume, of 145,700 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Trading Down 2.4 %

Shares of ALGS traded down $0.46 during trading hours on Friday, hitting $19.00. 220,922 shares of the stock traded hands, compared to its average volume of 69,398. The business has a fifty day moving average of $10.11 and a 200-day moving average of $12.51. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The firm had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same period last year, the company posted ($10.25) earnings per share. As a group, research analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of large investors have recently modified their holdings of the business. Acadian Asset Management LLC boosted its position in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the last quarter. Finally, Opaleye Management Inc. raised its holdings in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).